The use of recently approved antiepileptic drugs: Use with caution, use in refractory patients or use as first-line indications?

Expert Review of Neurotherapeutics

Volumn 11, Issue 12, 2011, Pages 1759-1767

  Beghi, Ettore ^a   Beghi, Massimiliano ^b,c   Cornaggia, Cesare Maria ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b RHO HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

efficacy; epilepsy; indications; new antiepileptic drugs; safety

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; BROMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENACEMIDE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ATAXIA; BLOOD TOXICITY; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONGENITAL MALFORMATION; DEPRESSION; DISEASE CONTROL; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FOCAL EPILEPSY; HISTORY; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; NAUSEA; NONHUMAN; PROGNOSIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SOMNOLENCE; TERATOGENICITY; TREATMENT RESPONSE;

ANTICONVULSANTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG DISCOVERY; EPILEPSY; HUMANS; PROGNOSIS; TIME FACTORS;

EID: 81755187627     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.169     Document Type: Review

References (70)

1. Abimbola S, Martiniuk AL, Hackett ML, Anderson CS. The influence of design and definition on the proportion of general epilepsy cohorts with remission and intractability. Neuroepidemiology 36, 204-212 (2011).
2. Rodin EA. The Prognosis of Patients with Epilepsy. Charles C. Thomas Springfield, IL, USA (1968).
3. Sillanpää M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain 132, 989-998 (2009).
4. Geerts A, Arts WF, Stroink H et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch study of epilepsy in childhood. Epilepsia 51, 1189-1197 (2011).
5. Berg AT, Shinnar S, Levy SR et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia 42, 1553-1562 (2001).
6. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann. Neurol. 48, 833-841 (2000).
7. Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia 33, 45-51 (1992).
8. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 20, 729-737 (1979).
9. Camfield PR, Camfield CS, Gordon K, Dooley JM. If a first antiepileptic drug fails to control a child's epilepsy, what are the chances of success with the next drug? J. Pediatr. 131, 821-824 (1997).
10. Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 57, 2259-2264 (2001).
11. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342, 314-319 (2000).
12. Choi H, Heiman GA, Munger Clary H, Etienne M, Resor SR, Hauser WA. Seizure remission in adults with long-standing intractable epilepsy: an extended follow-up. Epilepsy Res. 93, 115-119 (2011).
13. Del Felice A, Beghi E, Boero G et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia 51, 37-42 (2010).
14. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-βased study. Brain 129, 617-624 (2006).
15. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol. 62, 382-389 (2007).
16. Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann. Neurol. 62, 375-381 (2007).
17. Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia 50(Suppl. 3), 69-92 (2009).
18. Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 50(Suppl. 3), 93-130 (2009).
19. Arroyo S. Rufinamide. Neurotherapeutics 4, 155-162 (2007).
20. Perucca E. An introduction to antiepileptic drugs. Epilepsia 46(Suppl. 4), 31-37 (2005).
21. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5, 553-564 (2004).
22. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 25, 89-107 (2011).
23. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev. Neurother. 10, 119-140 (2010).
24. Schmitz B, Montouris G, Schauble B, Caleo S. Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control. Epilepsia 51, 2231-2240 (2010).
25. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin. Pharmacokinet. 45, 351-363 (2006).
26. Beghi E, Atzeni L, Garattini L Economic analysis of newer antiepileptic drugs. CNS Drugs 22, 861-875 (2008).
27. Costa J, Fareleira F, Ascencao R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 52, 1280-1291 (2011).
28. Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev. 1, CD005612 (2008).
29. Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy (review). Cochrane Database Syst. Rev. 3, CD007302 (2008).
30. Jette N, Hemming K, Hutton JL, Marson AG. Topiramate add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev. 2, CD001417 (2008).
31. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev. 2, CD001416 (2005).
32. Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev. 3, CD001908 (2002).
33. Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization-related (partial) epilepsy (review). Cochrane Database Syst. Rev. 1, CD001901 (2001).
34. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev. 3, CD001909 (2001).
35. Castillo SM, Schmidt DB, White S, Shukralla A. Oxcarbazepine add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev. 3, CD002028 (2000).
36. Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369(9566), 1000-1015 (2007).
37. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy (review). Cochrane Database Syst. Rev. 1, CD001031 (2006).
38. Saetre E, Perucca E, Isojärvi J, Gjerstad L; LAM 40089 Study Group. An international multicenter randomized double-βlind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 48, 1292-1302 (2007).
39. Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369(9566), 1016-1026 (2007).
40. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68, 402-408 (2007).
41. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S; EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-βlind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. 107, 165-175 (2003).
42. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-βlind study. Vigabatrin European Monotherapy Study Group. Lancet 354, 13-19 (1999).
43. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-βased analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47, 1094-1120 (2006).
44. French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62, 1261-1273 (2004).
45. Pellock JM, Hrachovy R, Shinnar S et al. Infantile spasms: a US. consensus report. Epilepsia 51, 2175-2189 (2010).
46. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst. Rev. 4, CD001770 (2008).
47. Dravet C. Dravet syndrome history. Dev. Med. Child Neurol. 53(Suppl. 2), 1-6 (2011).
48. Kassaï B, Chiron C, Augier S et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 49, 343-348 (2008).
49. Arzimanoglou A, French J, Blume WT et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 8, 82-93 (2009).
50. Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst. Rev. 3, CD003277 (2009).
51. Verrotti A, Loiacono G, Ballone E, Mattei PA, Chiarelli F, Curatolo P. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr. Neurol. 44, 347-349 (2011).
52. Prunetti P, Perucca E. New and forthcoming anti-epileptic drugs. Curr. Opin. Neurol. 24, 159-164 (2011).
53. Depositario-Cabacar DF, Zelleke TG. Treatment of epilepsy in children with developmental disabilities. Dev. Disabil. Res. Rev. 16, 239-247 (2010).
54. Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities (review). Cochrane Database Syst. Rev. 3, CD005399 (2007).
55. Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 38, 1265-1269 (1997).
56. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64, 1134-1138 (2005).
57. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 50, 163-173 (2009).
58. Tomson T, Battino D, Bonizzoni E et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 10, 609-617 (2011).
59. Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305, 1996-2002 (2011).
60. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 6, 57-75 (2004).
61. Amann B, Born C, Crespo JM, Pomarol- Clotet E, McKenna P. Lamotrigine: when and where does it act in affective disorders? A systematic review. J. Psychopharmacol. doi:10.1177/0269881110376695 (2010) (Epub ahead of print).
62. Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs; what can we learn from long-term studies? Acta Neurol. Scand. 114, 157-168 (2006).
63. Weijenberg A. Offringa M, Brouwer OF, Callenbach PM. RCTs with new antiepileptic drugs in children: a systematic review of monotherapy studies and their methodology. Epilepsy Res. 91, 1-19 (2010).
64. Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav. 13, 156-161 (2008).
65. Brodie MJ, Chadwick DW, Anhut H et al. Gabapentin versus lamotrigine monotherapy: a double-βlind comparison in newly diagnosed epilepsy. Epilepsia 43, 993-1000 (2002).
66. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 42, 1255-1260 (2001).
67. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 35, 1230-1243 (1994).
68. Glauser TA, Cnaan A, Shinnar S et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N. Engl. J. Med. 362, 790-799 (2010).
69. Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52, 657-678 (2011).
70. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 9, 68-82 (2010).